Press & News

The next generation biopharmaceuticals

Press releases 2017

2017-12-01

Bästa aktieägare i Affibody Medical AB

Vid extra bolagsstämma i bolaget den 23 november i år beslöts att genomföra en nyemission av aktier i bolaget.[read more]

Older press releases

2017-11-17

Interim Report – January to September 2017

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the third quarter 2017[read more]

2017-11-08

Kallelse till extra bolagsstämma

Aktieägarna i Affibody Medical AB (publ) kallas härmed till extra bolagsstämma torsdagen den 23 november 2017 kl 16.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.[read more]

2017-09-06

Affibody Announces Presentation of Interim Data from Phase I/II Clinical Trial of ABY-035 at European Academy of Dermatology and Venereology

Solna, Sweden, September 6, 2017. Affibody AB (“Affibody”), a clinical stage next generation biopharmaceutical company developing a portfolio of innovative drug projects, today announced that interim data from the ongoing Phase I/II study of ABY-035 will be presented at...[read more]

Affibodys latest Press releases

2018-09-24

New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment

Solna, Sweden, September 24, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report Q2 (August 23, 2018)

Investor information